ResearcherShanghai Medical College of Fudan UniversityNo recent work listed
Jinfeng Xiang
Matched on OpenAlex author ID A5112310715. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 48
2015: 1 paper · 2016: 3 papers · 2017: 5 papers · 2018: 2 papers · 2019: 1 paper
Papers 12
- ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. Co-author DOI 10.1097/mpa.0000000000001408↗
- TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
- dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
- ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.12.014↗
- Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
- A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
- FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Co-author DOI 10.3892/or.2017.5856↗
- Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
- Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2016.09.001↗
- Energy sources identify metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1093/abbs/gmw097↗
- The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… First author DOI 10.3892/ijo.2015.3316↗
- Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Co-author DOI 10.1016/j.canlet.2015.01.023↗
Closest collaborators
The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xianjun Yu · 12 shared papers, 2015–2019 · strength 0.72
- Paper ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer I… DOI 10.1097/mpa.0000000000001408↗
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Wenyan Xu · 10 shared papers, 2016–2019 · strength 0.63
- Paper ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer I… DOI 10.1097/mpa.0000000000001408↗
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Shunrong Ji · 10 shared papers, 2016–2019 · strength 0.63
- Paper ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer I… DOI 10.1097/mpa.0000000000001408↗
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Yi Qin · 10 shared papers, 2016–2019 · strength 0.63
- Paper ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer I… DOI 10.1097/mpa.0000000000001408↗
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Quanxing Ni · 11 shared papers, 2015–2018 · strength 0.63
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. DOI 10.3892/or.2017.5856↗
- Jin Xu · 10 shared papers, 2015–2018 · strength 0.59
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. DOI 10.3892/or.2017.5856↗
- Qiangsheng Hu · 8 shared papers, 2016–2018 · strength 0.48
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. DOI 10.3892/or.2017.5856↗
- Chen Liang · 8 shared papers, 2016–2018 · strength 0.47
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. DOI 10.3892/or.2017.5856↗
- Paper Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-A… DOI 10.7150/jca.18901↗
- Dingkong Liang · 8 shared papers, 2016–2018 · strength 0.47
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. DOI 10.3892/or.2017.5856↗
- Paper Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-A… DOI 10.7150/jca.18901↗
- Si Shi · 8 shared papers, 2016–2018 · strength 0.47
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. DOI 10.3892/or.2017.5856↗
- Paper Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-A… DOI 10.7150/jca.18901↗
- Bo Zhang · 3 shared papers, 2017–2018 · strength 0.20
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-A… DOI 10.7150/jca.18901↗
- Paper Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1541-7786.mcr-16-0296↗
- Wensheng Liu · 3 shared papers, 2017–2018 · strength 0.19
- Paper dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. DOI 10.1111/cpr.12456↗
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. DOI 10.3892/ijo.2017.3938↗
- Liang Liu · 4 shared papers, 2015–2017 · strength 0.19
- Paper A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. DOI 10.3892/ijo.2017.3938↗
- Paper Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. DOI 10.1016/j.canlet.2015.01.023↗
- Paper Energy sources identify metabolic phenotypes in pancreatic cancer. DOI 10.1093/abbs/gmw097↗
- Qingcai Meng · 3 shared papers, 2017–2018 · strength 0.18
- Paper TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. DOI 10.1038/s41419-018-0367-6↗
- Paper Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-A… DOI 10.7150/jca.18901↗
- Paper A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. DOI 10.3892/ijo.2017.3938↗
- Qiqing Sun · 2 shared papers, 2018–2019 · strength 0.16
- Chen Liu · 3 shared papers, 2015–2017 · strength 0.15
- Paper A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. DOI 10.3892/ijo.2017.3938↗
- Paper Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. DOI 10.1016/j.canlet.2015.01.023↗
- Paper Energy sources identify metabolic phenotypes in pancreatic cancer. DOI 10.1093/abbs/gmw097↗
- Jiang Long · 2 shared papers, 2015–2017 · strength 0.10
- Mengqi Liu · 1 shared paper, 2019 · strength 0.09
- Xiaowu Xu · 1 shared paper, 2019 · strength 0.09
- Zheng Zhang · 1 shared paper, 2018 · strength 0.07
- Bo Zhang · 1 shared paper, 2018 · strength 0.07
- Pengfei Hu · 1 shared paper, 2017 · strength 0.05
- Huaxiang Xu · 1 shared paper, 2015 · strength 0.05
- Wenquan Wang · 1 shared paper, 2015 · strength 0.05
- Chuntao Wu · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.